Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lamotrigine
Drug ID BADD_D01243
Description Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries.[A191350] Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850]
Indications and Usage Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.[L9404] It is also indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).[L9404] In addition to the above, lamotrigine is also indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been treated for acute mood symptoms with standard therapy.[L9404] Limitations of use It is important to note that lamotirigine should not be used in the treatment of acute mood episodes, as efficacy has not been established in this context.[L9404]
Marketing Status approved; investigational
ATC Code N03AX09
DrugBank ID DB00555
KEGG ID D00354
MeSH ID D000077213
PubChem ID 3878
TTD Drug ID D03FLC
NDC Product Code 17511-103; 58437-020; 58437-021; 65862-228; 65862-266; 66406-0283; 16714-197; 16714-626; 0115-1527; 0115-1529; 42291-368; 0173-0643; 0173-0699; 0173-0759; 49884-880; 51655-719; 53002-2513; 55111-222; 55111-223; 55154-2065; 62332-040; 65162-990; 68071-2873; 68071-2960; 68382-009; 68462-228; 69102-137; 69102-301; 69102-312; 69918-370; 70518-1978; 70518-2716; 71335-1110; 0615-8267; 12666-0005; 0904-7007; 0904-7008; 59285-023; 59917-077; 27241-185; 0115-1528; 42291-448; 43598-550; 0173-0527; 0173-0756; 0173-0777; 0173-0778; 49884-484; 49884-487; 50090-3914; 0228-1435; 0228-1453; 55111-226; 63187-487; 63629-4697; 63629-8283; 65841-685; 65841-686; 69102-300; 69102-306; 69102-320; 69918-360; 70518-2563; 70518-2697; 70518-3425; 0615-7975; 0615-8150; 72789-206; 53296-0059; 16714-700; 42291-444; 42291-447; 43063-238; 0173-0594; 0173-0644; 0173-0757; 0173-0758; 46708-275; 46708-276; 49884-486; 50228-322; 55111-220; 55111-428; 55111-717; 55154-2331; 55700-626; 65162-986; 68071-2054; 68071-2729; 68382-980; 68462-229; 70518-3139; 70518-3602; 71335-0044; 55111-419; 60687-693; 65841-687; 67877-167; 68382-008; 68382-011; 68382-982; 68382-983; 68382-984; 68788-8392; 69097-151; 70518-2503; 70518-2535; 70518-3187; 70518-3740; 71335-0830; 58437-022; 65015-626; 65862-229; 66406-0281; 68022-7036; 13668-266; 27241-186; 29300-112; 29300-113; 42291-367; 0173-0633; 0173-0781; 49884-882; 50090-2129; 50090-6028; 51672-4132; 58118-1111; 58118-2148; 59746-245; 59746-246; 60760-543; 61919-534; 62332-096; 65162-988; 67877-164; 68382-006; 68382-979; 68788-6868; 68788-7223; 69097-149; 69102-319; 70518-2889; 70518-3043; 70934-975; 71335-2071; 72888-025; 72888-028; 65862-230; 13668-049; 13668-342; 16714-196; 42291-369; 0173-0772; 0173-0780; 46708-277; 50090-2131; 50090-5827; 0228-1410; 0228-1638; 53002-1512; 59746-247; 65841-689; 65862-227; 67877-166; 68084-318; 69102-639; 70518-2406; 70518-3109; 71205-245; 71335-0706; 0615-7964; 76420-182; 51552-1361; 51927-0021; 59917-079; 65372-1103; 13668-339; 13668-340; 27241-183; 27241-184; 42291-446; 43598-553; 0173-0761; 49884-881; 50090-2130; 50090-5850; 50228-320; 51672-4133; 53002-2512; 60687-704; 63187-744; 65841-682; 65841-683; 68382-010; 68382-109; 68788-7544; 70518-2755; 71335-1919; 72189-063; 72888-027; 14799-2011; 16714-624; 29300-114; 42291-366; 43598-551; 43598-552; 0173-0754; 0173-0776; 0228-1580; 59746-248; 62332-037; 62332-038; 65162-956; 65862-361; 67877-165; 68788-7168; 69097-152; 69918-380; 70518-1479; 72888-026; 42419-012; 58437-019; 59917-078; 62331-047; 66406-0284; 67835-0016; 13668-045; 13668-048; 13668-341; 16714-195; 16714-702; 16714-703; 16714-893; 0115-1526; 43063-203; 0173-0526; 0173-0755; 0173-0760; 0173-0779; 51672-4131; 55111-719; 55154-2330; 65162-958; 65841-684; 65841-690; 65862-362; 68071-2974; 68382-108; 68382-981; 69102-150; 69102-359; 69918-350; 70518-1523; 71335-1179; 55111-043; 58437-024; 59917-080; 66406-0282; 16571-786; 16714-625; 16714-627; 16714-701; 29300-111; 42291-445; 0173-0774; 0173-0817; 46708-274; 0228-1422; 51672-4130; 55111-225; 55700-683; 62332-039; 62332-095; 65162-949; 68084-319; 68382-007; 68788-7647; 69097-148; 70518-1908; 70518-2108; 70518-3150; 71335-1469; 80425-0289; 53104-7606; 53747-016; 58437-023; 82891-004; 13668-047; 16571-785; 16714-194; 16714-623; 42291-443; 0173-0642; 49884-485; 50228-319; 50228-321; 51655-855; 53002-1513; 55111-221; 55111-718; 55111-720
UNII U3H27498KS
Synonyms Lamotrigine | 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine | 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine | Lamictal | Crisomet | Lamiktal | BW-430C | BW 430C | BW430C | Labileno
Chemical Information
Molecular Formula C9H7Cl2N5
CAS Registry Number 84057-84-1
SMILES C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphemia17.02.08.010; 19.19.03.0050.000177%Not Available
Foetal death08.04.01.011; 18.01.02.0030.000276%
Haemorrhage24.07.01.002--Not Available
Fluid intake reduced14.05.10.0010.000083%Not Available
Cutaneous lupus erythematosus15.06.02.007; 10.04.03.007; 23.03.02.0080.000083%Not Available
Vulvovaginal pruritus23.03.12.009; 21.08.02.0040.000083%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000083%Not Available
Pharyngeal erythema22.04.05.0100.000342%Not Available
Temperature intolerance08.01.09.0220.000055%Not Available
Neonatal tachypnoea22.11.01.003; 18.04.09.0030.000221%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000204%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Bipolar disorder19.16.01.0030.000414%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.001060%
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.001242%Not Available
Precocious puberty21.03.02.009; 05.05.03.0010.000055%
Ocular icterus01.06.04.007; 09.01.01.007; 06.08.03.0090.000166%Not Available
Dysgraphia17.02.03.0060.000083%Not Available
Nuchal rigidity17.05.02.006; 15.05.04.0050.000083%Not Available
Skin oedema23.06.04.0010.000083%Not Available
Vasodilation procedure25.03.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Epidermal necrosis23.03.03.0350.000359%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Neurological symptom17.02.05.0100.000248%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
The 26th Page    First    Pre   26 27 28 29 30    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene